vs
Side-by-side financial comparison of KORU Medical Systems, Inc. (KRMD) and Lakeside Holding Ltd (LSH). Click either name above to swap in a different company.
KORU Medical Systems, Inc. is the larger business by last-quarter revenue ($11.8B vs $7.0M, roughly 1677.6× Lakeside Holding Ltd). On growth, Lakeside Holding Ltd posted the faster year-over-year revenue change (95.0% vs 22.1%).
KORU Medical Systems, Inc. is a specialized medical technology company that designs, manufactures, and distributes innovative ambulatory infusion systems and supporting disposable products. It caters to healthcare providers and patients across home care, clinical trial, and acute care segments worldwide, with a focus on enhancing the safety and comfort of specialty medication delivery.
Lakeside Press was a Chicago publishing imprint under which the RR Donnelley Company produced fine books as well as mail order catalogs, telephone directories, encyclopedias, and advertising. The Press was best known for its high quality editions for the Chicago Caxton Club as well as the Lakeside Classics, a series of fine reprints.
KRMD vs LSH — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.8B | $7.0M |
| Net Profit | — | $-1.6M |
| Gross Margin | 61.5% | 27.2% |
| Operating Margin | 31.2% | -21.3% |
| Net Margin | — | -22.6% |
| Revenue YoY | 22.1% | 95.0% |
| Net Profit YoY | — | 18.7% |
| EPS (diluted) | — | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $11.8B | — | ||
| Q4 25 | $10.9M | $7.0M | ||
| Q3 25 | $10.4M | $6.1M | ||
| Q2 25 | $10.2M | $6.3M | ||
| Q1 25 | $9.6M | $3.8M | ||
| Q4 24 | $8.8M | $3.6M | ||
| Q3 24 | $8.2M | $4.1M | ||
| Q2 24 | $8.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $-1.6M | ||
| Q3 25 | $-778.0K | $-1.4M | ||
| Q2 25 | $-206.9K | $-893.1K | ||
| Q1 25 | $-1.2M | $-1.1M | ||
| Q4 24 | — | $-1.9M | ||
| Q3 24 | $-1.6M | $-1.3M | ||
| Q2 24 | $-988.7K | — |
| Q1 26 | 61.5% | — | ||
| Q4 25 | 62.6% | 27.2% | ||
| Q3 25 | 60.2% | 18.2% | ||
| Q2 25 | 63.5% | 26.7% | ||
| Q1 25 | 62.8% | 18.8% | ||
| Q4 24 | 62.9% | -1.2% | ||
| Q3 24 | 63.4% | 12.8% | ||
| Q2 24 | 65.0% | — |
| Q1 26 | 31.2% | — | ||
| Q4 25 | -5.0% | -21.3% | ||
| Q3 25 | -8.3% | -20.8% | ||
| Q2 25 | -3.1% | -8.9% | ||
| Q1 25 | -12.9% | -28.2% | ||
| Q4 24 | -18.0% | -55.6% | ||
| Q3 24 | -20.8% | -32.5% | ||
| Q2 24 | -14.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | -22.6% | ||
| Q3 25 | -7.5% | -22.2% | ||
| Q2 25 | -2.0% | -14.2% | ||
| Q1 25 | -12.1% | -28.2% | ||
| Q4 24 | — | -54.1% | ||
| Q3 24 | -19.3% | -32.7% | ||
| Q2 24 | -11.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | $-0.11 | $-0.08 | ||
| Q3 25 | $0.02 | $-0.09 | ||
| Q2 25 | $0.00 | $-0.11 | ||
| Q1 25 | $0.03 | $-0.14 | ||
| Q4 24 | $-0.22 | $-0.26 | ||
| Q3 24 | $0.03 | $-0.18 | ||
| Q2 24 | $0.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.8B | $1.6M |
| Total DebtLower is stronger | — | $2.4M |
| Stockholders' EquityBook value | — | $12.2M |
| Total Assets | $28.6B | $24.3M |
| Debt / EquityLower = less leverage | — | 0.20× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $8.8B | — | ||
| Q4 25 | $8.9M | $1.6M | ||
| Q3 25 | $8.5M | $4.5M | ||
| Q2 25 | $8.1M | $5.0M | ||
| Q1 25 | $8.7M | $1.5M | ||
| Q4 24 | $9.6M | $1.1M | ||
| Q3 24 | $8.8M | $2.7M | ||
| Q2 24 | $10.5M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $774.2K | ||
| Q4 24 | — | $784.8K | ||
| Q3 24 | — | $589.9K | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $17.0M | $12.2M | ||
| Q3 25 | $16.5M | $7.0M | ||
| Q2 25 | $16.5M | $2.8M | ||
| Q1 25 | $16.3M | $749.8K | ||
| Q4 24 | $16.8M | $1.6M | ||
| Q3 24 | $17.7M | $3.6M | ||
| Q2 24 | $18.7M | — |
| Q1 26 | $28.6B | — | ||
| Q4 25 | $28.2M | $24.3M | ||
| Q3 25 | $27.1M | $18.6M | ||
| Q2 25 | $25.5M | $14.4M | ||
| Q1 25 | $27.2M | $9.9M | ||
| Q4 24 | $27.2M | $9.8M | ||
| Q3 24 | $27.4M | $10.8M | ||
| Q2 24 | $27.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.48× | ||
| Q1 25 | — | 1.03× | ||
| Q4 24 | — | 0.48× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-453.5K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.1M | $-453.5K | ||
| Q3 25 | $65.5K | $-4.0M | ||
| Q2 25 | $-460.3K | $-483.7K | ||
| Q1 25 | $-237.5K | $-238.3K | ||
| Q4 24 | $939.6K | $-530.2K | ||
| Q3 24 | $-923.9K | $-1.4M | ||
| Q2 24 | $11.3K | — |
| Q1 26 | — | — | ||
| Q4 25 | $687.0K | — | ||
| Q3 25 | $13.0K | — | ||
| Q2 25 | $-489.2K | $-497.4K | ||
| Q1 25 | $-680.9K | — | ||
| Q4 24 | $896.0K | $-560.5K | ||
| Q3 24 | $-2.0M | $-1.4M | ||
| Q2 24 | $-112.9K | — |
| Q1 26 | — | — | ||
| Q4 25 | 6.3% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | -4.8% | -7.9% | ||
| Q1 25 | -7.1% | — | ||
| Q4 24 | 10.1% | -15.6% | ||
| Q3 24 | -24.5% | -34.5% | ||
| Q2 24 | -1.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | 3.7% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.3% | 0.2% | ||
| Q1 25 | 4.6% | 0.0% | ||
| Q4 24 | 0.5% | 0.8% | ||
| Q3 24 | 13.2% | 0.1% | ||
| Q2 24 | 1.5% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KRMD
Segment breakdown not available.
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
